journal article·2020

Albumin-driven disassembly of lipidic nanoparticles: the specific case of the squalene-adenosine nanodrug

Frédéric Gobeaux, Joëlle Bizeau, Firmin Samson, Laurent Marichal, Isabelle Grillo, Frank Wien, Semen O. Yesylevsky, Christophe Ramseyer, Marie Rouquette, Sinda Lepêtre-Mouelhi, Didier Desmaële, Patrick Couvreur, Patrick Guenoun, Jean-Philippe Renault, Fabienne Testard

Nanoscale· Volume 12· Issue 4
Publisher page

Abstract

In the field of nanomedicine, nanostructured nanoparticles (NPs) made of self-assembling prodrugs emerged in the recent years with promising properties. In particular, squalene-based drug nanoparticles have already shown their efficiency through in vivo experiments. However, a complete pattern of their stability and interactions in the blood stream is still lacking. In this work we assess the behavior of squalene-adenosine (SQAd) nanoparticles - whose neuroprotective effect has already been demonstrated in murine models - in the presence of fetal bovine serum (FBS) and of bovine serum albumin (BSA), the main protein of blood plasma. Extensive physicochemical characterizations were performed using Small Angle Neutron Scattering (SANS), cryogenic transmission electron microscopy (Cryo-TEM), circular dichroism (CD), steady-state fluorescence spectroscopy (SSFS) and isothermal titration calorimetry (ITC) as well as in silico by means of ensemble docking simulations with human serum albumin (HSA). Significant changes in the colloidal stability of the nanoparticles in the presence of serum albumin were observed. SANS, CD and SSFS analyses demonstrated an interaction between SQAd and BSA, with a partial disassembly of the nanoparticles in the presence of BSA and the formation of a complex between SQAd and BSA. The interaction free energy of SQAd nanoparticles with BSA derived from ITC experiments, is about -8 kcal mol-1 which is further supported in silico by ensemble docking simulations. Overall, our results show that serum albumin partially disassembles SQAd nanoparticles by extracting individual SQAd monomers from them. As a consequence, the SQAd nanoparticles would act as a circulating reservoir in the blood stream. The approach developed in this study could be extended to other soft organic nanoparticles.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery · Lipid Membrane Structure and Behavior

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

LIONS – NIMBE CEA

CNRS

Université Paris-Saclay

91191 Gif-sur-Yvette Cedex

France

Institut Laue Langevin

38042 Grenoble Cedex 9

SOLEIL Synchrotron

Saint Aubin

Department of Physics of Biological Systems

Institute of Physics of the National Academy of Sciences of Ukraine

03028 Kyiv

Ukraine

Laboratoire Chrono Environnement UMR CNRS 6249

Université de Bourgogne Franche-Comté

25030 Besançon Cedex

Institut Galien Paris-Sud

UMR 8612

Université Paris-Sud

Funding

Agence Nationale de la Recherche · Horizon 2020 Framework Programme

References (87)

Show source-provided references
1. Barua · Nano Today · 2014 · 9 · 22310.1016/j.nantod.2014.04.008 ↗
2. Barenholz (Chezy) · J. Controlled Release · 2012 · 160 · 11710.1016/j.jconrel.2012.03.020 ↗
3. Arvinte · mAbs · 2013 · 5 · 49110.4161/mabs.24245 ↗
4. T. Arvinte , Aggregation of Therapeutic Proteins after Mixing with Human Plasma: Implications for Drug Development , 2014
5. Rausch · Biomacromolecules · 2010 · 11 · 283610.1021/bm100971q ↗
6. Mohr · J. Nanomed. Nanotechnol. · 2014 · 05 · 19310.4172/2157-7439.1000193 ↗
7. Moore · Chem. Soc. Rev. · 2015 · 44 · 628710.1039/C4CS00487F ↗
8. Wei · J. Controlled Release · 2018 · 278 · 6610.1016/j.jconrel.2018.03.024 ↗
9. Nel · Nat. Mater. · 2009 · 8 · 54310.1038/nmat2442 ↗
10. Tenzer · Nat. Nanotechnol. · 2013 · 8 · 77210.1038/nnano.2013.181 ↗
11. Bertrand · Nat. Commun. · 2017 · 8 · 77710.1038/s41467-017-00600-w ↗
12. Ke · ACS Nano · 2017 · 11 · 1177310.1021/acsnano.7b08008 ↗
13. Salvati · Nat. Nanotechnol. · 2013 · 8 · 13710.1038/nnano.2012.237 ↗
14. Mirshafiee · Chem. Commun. · 2013 · 49 · 255710.1039/c3cc37307j ↗
15. Raesch · ACS Nano · 2015 · 9 · 1187210.1021/acsnano.5b04215 ↗
16. Klein · Nanotoxicology · 2016 · 10 · 155510.1080/17435390.2016.1244299 ↗
17. Docter · Nat. Protoc. · 2014 · 9 · 203010.1038/nprot.2014.139 ↗
18. Issaq · Chem. Rev. · 2007 · 107 · 360110.1021/cr068287r ↗
19. Anderson · Mol. Cell. Proteomics · 2002 · 1 · 84510.1074/mcp.R200007-MCP200 ↗
20. Emerson · Crit. Care Med. · 1989 · 17 · 69010.1097/00003246-198907000-00020 ↗
21. Fasano · IUBMB Life · 2008 · 57 · 78710.1080/15216540500404093 ↗
22. Wunder · J. Immunol. · 2003 · 170 · 479310.4049/jimmunol.170.9.4793 ↗
23. Larsen · Mol. Cell. Ther. · 2016 · 410.1186/s40591-016-0048-8 ↗
24. Paal · Eur. J. Biochem. · 2001 · 268 · 218710.1046/j.1432-1327.2001.02107.x ↗
25. Kratz · J. Controlled Release · 2008 · 132 · 17110.1016/j.jconrel.2008.05.010 ↗
26. Elsadek · J. Controlled Release · 2012 · 157 · 410.1016/j.jconrel.2011.09.069 ↗
27. Kratz · J. Controlled Release · 2014 · 190 · 33110.1016/j.jconrel.2014.03.013 ↗
28. Couvreur · Nano Lett. · 2006 · 6 · 254410.1021/nl061942q ↗
29. Bildstein · Soft Matter · 2010 · 6 · 557010.1039/c0sm00342e ↗
30. Desmaële · J. Controlled Release · 2012 · 161 · 60910.1016/j.jconrel.2011.07.038 ↗
31. Lepeltier · Langmuir · 2013 · 29 · 1479510.1021/la403338y ↗
32. Sobot · Nat. Commun. · 2017 · 8 · 1567810.1038/ncomms15678 ↗
33. Gaudin · Nat. Nanotechnol. · 2014 · 9 · 105410.1038/nnano.2014.274 ↗
34. Gaudin · J. Controlled Release · 2015 · 212 · 5010.1016/j.jconrel.2015.06.016 ↗
35. Jacobson · Nat. Rev. Drug Discovery · 2006 · 5 · 24710.1038/nrd1983 ↗
36. Chen · Nat. Rev. Drug Discovery · 2013 · 12 · 26510.1038/nrd3955 ↗
37. Sobot · Nat. Commun. · 2017 · 8 · 1567810.1038/ncomms15678 ↗
38. Rouquette · J. Pharmacol. Exp. Ther. · 2019 · 118 · 25496110.1124/jpet.118.254961 ↗
39. Sobot · Mol. Ther. · 2017 · 25 · 159610.1016/j.ymthe.2017.05.016 ↗
40. Yesylevskyy · Mol. Pharm. · 2018 · 15 · 58510.1021/acs.molpharmaceut.7b00952 ↗
41. Mathé · PLoS One · 2013 · 8 · e8134610.1371/journal.pone.0081346 ↗
42. Klein · Langmuir · 2016 · 32 · 19510.1021/acs.langmuir.5b03890 ↗
43. Devineau · Langmuir · 2017 · 33 · 324110.1021/acs.langmuir.6b04281 ↗
44. Leesajakul · Colloids Surf., B · 2004 · 34 · 25310.1016/j.colsurfb.2004.01.010 ↗
45. Bode · Int. J. Pharm. · 2013 · 448 · 8710.1016/j.ijpharm.2013.03.016 ↗
46. Couvreur · Small · 2008 · 4 · 24710.1002/smll.200700731 ↗
47. Saha · Soft Matter · 2015 · 11 · 417310.1039/C5SM00592B ↗
48. Guyon · J. Phys. Chem. Lett. · 2019 · 10 · 661310.1021/acs.jpclett.9b01493 ↗
49. Di Cola · Pharmaceutics · 2016 · 8 · 1010.3390/pharmaceutics8020010 ↗
50. Endo · Physica B: Condens. Matter · 2006 · 385–386 · 68210.1016/j.physb.2006.05.290 ↗
51. Yadav · Phys. Rev. E · 2016 · 93 · 05260110.1103/PhysRevE.93.052601 ↗
52. Yadav · Phys. Rev. E · 2015 · 91 · 05230610.1103/PhysRevE.91.052306 ↗
53. Kokkinopoulou · Nanoscale · 2017 · 9 · 885810.1039/C7NR02977B ↗
54. Kumar · Langmuir · 2018 · 34 · 567910.1021/acs.langmuir.8b00110 ↗
55. Kelly · Biochim. Biophys. Acta, Proteins Proteomics · 2005 · 1751 · 11910.1016/j.bbapap.2005.06.005 ↗
56. Kelly · Biochim. Biophys. Acta, Proteins Proteomics · 1997 · 1138 · 16110.1016/S0167-4838(96)00190-2 ↗
57. Follmann · Eur. J. Biochem. · 1975 · 58 · 3110.1111/j.1432-1033.1975.tb02345.x ↗
58. Micsonai · Proc. Natl. Acad. Sci. U. S. A. · 2015 · 112 · E309510.1073/pnas.1500851112 ↗
59. Fleischer · J. Phys. Chem. B · 2014 · 118 · 1401710.1021/jp502624n ↗
60. Ghosh · J. Phys. Chem. B · 2015 · 119 · 780410.1021/acs.jpcb.5b00965 ↗
61. Belatik · Eur. J. Med. Chem. · 2012 · 11410.1016/j.ejmech.2011.12.002 ↗
62. Lin · Biopolymers · 1976 · 15 · 20310.1002/bip.1976.360150114 ↗
63. Takeda · J. Protein Chem. · 1989 · 8 · 65310.1007/BF01025605 ↗
64. Borzova · PLoS One · 2016 · 11 · e015349510.1371/journal.pone.0153495 ↗
65. Mortimer · ACS Nano · 2014 · 8 · 335710.1021/nn405830g ↗
66. Ramadass · Mol. Immunol. · 2015 · 64 · 5510.1016/j.molimm.2014.10.022 ↗
67. T. Peters Jr. , 2 – The Albumin Molecule: Its Structure and Chemical Properties , in All About Albumin , Academic Press , San Diego , 1995 , p. 9–II . 10.1016/B978-012552110-9/50004-010.1016/B978-012552110-9/50004-0 ↗
68. J. R. Lakowicz , in Principles of Fluorescence Spectroscopy , Springer , New York, N.Y. , 3rd edn, 200610.1007/978-0-387-46312-4 ↗
69. Biophysical and Biochemical Aspects of Fluorescence Spectroscopy , ed. T. G. Dewey , Springer , New York , 1991
70. Jahanban-Esfahlan · Food Chem. · 2016 · 202 · 42610.1016/j.foodchem.2016.02.026 ↗
71. U. Kragh-Hansen , The Albumin website, Ligand Binding , http://albumin.org/ligand-binding/
72. Tarushi · Eur. J. Med. Chem. · 2014 · 74 · 18710.1016/j.ejmech.2013.12.019 ↗
73. Walkey · J. Am. Chem. Soc. · 2012 · 134 · 213910.1021/ja2084338 ↗
74. Amici · RSC Adv. · 2017 · 7 · 113710.1039/C6RA25493D ↗
75. Kihara · Bioconjugate Chem. · 2019 · 30 · 106710.1021/acs.bioconjchem.9b00015 ↗
76. Huang · J. Am. Soc. Mass Spectrom. · 2004 · 15 · 123710.1016/j.jasms.2004.05.004 ↗
77. Majorek · Mol. Immunol. · 2012 · 52 · 17410.1016/j.molimm.2012.05.011 ↗
78. Johari · Daru, J. Pharm. Sci. · 2014 · 22 · 7910.1186/s40199-014-0079-0 ↗
79. Bujacz · Acta Crystallogr., Sect. D: Biol. Crystallogr. · 2012 · 68 · 127810.1107/S0907444912027047 ↗
80. Iyer · Drug Discovery Today · 2006 · 11 · 81210.1016/j.drudis.2006.07.005 ↗
81. Richard · J. Neutron Res. · 1996 · 4 · 3310.1080/10238169608200065 ↗
82. Yesylevskyy · J. Chem. Inf. Model. · 2016 · 56 · 158810.1021/acs.jcim.6b00198 ↗
83. Pallandre · Eur. J. Med. Chem. · 2015 · 103 · 16310.1016/j.ejmech.2015.08.054 ↗
84. Yesylevskyy · Biopolym. Cell · 2012 · 28 · 48610.7124/bc.00013B ↗
85. Hassan · Sci. Rep. · 2017 · 7 · 1545110.1038/s41598-017-15571-7 ↗
86. Yesylevskyy · J. Comput. Chem. · 2012 · 33 · 163210.1002/jcc.22989 ↗
87. Yesylevskyy · J. Comput. Chem. · 2015 · 36 · 148010.1002/jcc.23943 ↗